Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05958082 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Primary completion date changed from estimate of Aug 2026 to Aug 1, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  2. Primary completion pushed from Jun 2026 to Aug 2026v6
  3. Primary completion date: Dec 2025 to Jun 2026
    • Study completion date: Jun 2026 to Dec 2026
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jun 2025 to Dec 2025
    • Start date changed from estimate of Dec 2024 to Jan 1, 2025
    • Site details revised
    v4
  5. Start date: Jun 2024 to Dec 2024v3
  6. Primary completion date: Oct 2024 to Jun 2025
    • Start date: Oct 2023 to Jun 2024
    • Study completion date: Oct 2026 to Jun 2026
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.
Trial Details
NCT Number NCT05958082
Lead Sponsor Henry Ford Health System
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov